On Thursday, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk A/S’ (NYSE:NVO) Awiqli (insulin icodec-abae), marking the first once-weekly basal insulin for adults with Type 2 diabetes.

The company positioned the therapy as a shift in diabetes care, potentially reducing the burden of daily injections while maintaining glycemic control.

FDA Clears First Once-Weekly Basal Insulin

The newly approved treatment is indicated as an adjunct to diet and exercise to improve blood sugar levels in adults with Type 2 diabetes.

Awiqli introduces a once-weekly dosing regimen, offering an alternative to traditional daily basal insulin therapies.

“Awiqli is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It’s helping to reframe what basal insulin care can look like,” ...